Clinical TrialMay 18, 2026, 06:32 AM
Perspective Therapeutics Doses First Patients in Two Phase 1/2a Trials
AI Summary
Perspective Therapeutics announced that the first patients were dosed in new cohorts for two of its Phase 1/2a clinical trials. The fourth cohort of the [212Pb]VMT-α-NET trial for neuroendocrine tumors will explore a front-loading dosing regimen to optimize response kinetics and improve efficacy. Additionally, the third cohort of the [212Pb]PSV359 trial for solid tumors has begun dosing after a safety review, aiming to assess safety and preliminary anti-tumor activity.
Key Highlights
- First patient dosed in Cohort 4 of [212Pb]VMT-α-NET Phase 1/2a trial for neuroendocrine tumors.
- Cohort 4 explores front-loading a 20 mCi cumulative dose (6.0, 5.0, 5.0, 4.0 mCi) to optimize response.
- First patient dosed in Cohort 3 of [212Pb]PSV359 Phase 1/2a trial for solid tumors.
- Cohort 3 patients receive up to four fixed doses of 6.0 mCi of [212Pb]PSV359 every eight weeks.
- Cohort 3 for [212Pb]PSV359 was cleared to open following a safety review of Cohort 2 data.
Price Impact
More from CATX